Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Keros Therapeutics ( (KROS) ) just unveiled an announcement.
On August 20, 2025, Keros Therapeutics announced that the U.S. FDA granted Orphan Drug designation to KER-065 for treating Duchenne muscular dystrophy (DMD). This designation highlights the unmet medical need for DMD patients and marks a significant milestone for Keros as they advance KER-065 into a Phase 2 clinical trial. The Orphan Drug status offers potential benefits like tax credits and market exclusivity, which could enhance Keros’ market positioning and operational strategy in developing treatments for rare diseases.
The most recent analyst rating on (KROS) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
Keros Therapeutics’ overall stock score reflects a balanced view of its financial stability and growth potential against valuation concerns and mixed technical signals. The company’s strong financial performance and promising corporate developments are offset by high valuation metrics and strategic uncertainties.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company aims to provide meaningful and potentially disease-modifying benefits to patients, with a focus on neuromuscular diseases and cytopenias.
Average Trading Volume: 518,445
Technical Sentiment Signal: Sell
Current Market Cap: $589.7M
See more insights into KROS stock on TipRanks’ Stock Analysis page.